BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tokunaga T, Tanaka M, Tanaka K, Narahara S, Kawasaki T, Yoshimaru Y, Nagaoka K, Watanabe T, Tateyama M, Naoe H, Sasaki Y, Tanaka Y. Modified albumin-bilirubin grade to predict eligibility for second-line therapies at progression on sorafenib therapy in hepatocellular carcinoma patients. Int J Clin Oncol 2021;26:922-32. [PMID: 33730200 DOI: 10.1007/s10147-020-01835-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Ochi H, Tani J, Tomonari T, Taniguchi T, Koizumi Y, Hirose A, Ogawa C, Hiraoka A, Morishita A, Moriya A, Hirooka M, Deguchi A, Symple Study Group. Sequential therapy including regorafenib for unresectable hepatocellular carcinoma: Effect of early relative changes in hepatic functional reserve after regorafenib administration on prognosis. Hepatol Res 2021;51:1219-28. [PMID: 34534398 DOI: 10.1111/hepr.13713] [Reference Citation Analysis]
2 Wang HW, Chuang PH, Su WP, Kao JT, Hsu WF, Lin CC, Huang GT, Lin JT, Lai HC, Peng CY. On-Treatment Albumin-Bilirubin Grade: Predictor of Response and Outcome of Sorafenib-Regorafenib Sequential Therapy in Patients with Unresectable Hepatocellular Carcinoma. Cancers (Basel) 2021;13:3758. [PMID: 34359658 DOI: 10.3390/cancers13153758] [Reference Citation Analysis]